1579514-06-9

1579514-06-9 structure

Name: BI-685509
Chemical Name: BI-685509
CAS Number: 1579514-06-9
Molecular Formula: C₃₄H₃₈N₄O₅
Molecular Weight: 582.69
Catalog: Research Areas Cardiovascular Disease
Create Date: 2023-05-11 20:33:03
Modify Date: 2025-08-24 10:20:28
BI-685509 is a potent and orally active sGC activator. BI-685509 restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. BI-685509 can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD)[1].

Name	BI-685509

Description	BI-685509 is a potent and orally active sGC activator. BI-685509 restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. BI-685509 can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD)[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	BI 685509 在用血红素氧化剂 ODQ (HY-101255) 处理的人和大鼠富含血小板的血浆中增加 cGMP，EC50 值分别为 467 nM 和 304 nM[1]。
In Vivo	BI 685509 (1, 3, 10, 30 mg/kg; p.o.) 与 Enalapril (HY-B0331) 共同给药以剂量依赖性方式降低蛋白尿和肾小球硬化的发生率[1]。 BI 685509 (30 mg/kg; p.o.) 减少大鼠单侧输尿管梗阻 (UUO) 模型中的肾小管间质纤维化[1]。 Animal Model: ZSF1 rat model[1] Dosage: 1, 3, 10, 30 mg/kg; 3 mg/kg (enalapril) Administration: Oral administration; daily Result: Reduced proteinuria and incidence of glomerular sclerosis in a dose-dependent manner. Animal Model: rat UUO model[1] Dosage: 30 mg/kg Administration: v Result: Reduced tubulointerstitial fibrosis in rat UUO model.
References	[1]. Reinhart GA, et, al. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease. J Pharmacol Exp Ther. 2023 Mar;384(3):382-392.

Molecular Formula	C₃₄H₃₈N₄O₅
Molecular Weight	582.69